Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 1, 2012, Pages 36-40

  Meredith, Ruby ^a   You, Zhiying ^a   Alvarez, Ronald ^a   Partridge, Edward ^a   Grizzle, William ^a   LoBuglio, Albert ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

cancer; intraperitoneal; ovarian; radioimmunotherapy

Indexed keywords

LUTETIUM 177; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 LU 177; MONOCLONAL ANTIBODY CC49 Y 90; PACLITAXEL; RECOMBINANT ALPHA2B INTERFERON; TAG 72 ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; DOSE RESPONSE; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; SERUM SICKNESS; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES, NEOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTOXINS; INFUSIONS, PARENTERAL; LUTETIUM; MICE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 84856918256     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1111     Document Type: Article

References (20)

1. Schlom J, Siler K, Milenic DE, et al. Monoclonal antibodybased therapy of a human tumor xenograft with a 177lutetiumlabeled immunoconjugate. Cancer Res 1991;51:2889.
2. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49. J Nucl Med 1996;37:1491.
3. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study. Gynecol Oncol 1997;65:94.
4. Greiner JW, Guadagni F, Hand PH, et al. Augmentation of tumor antigen expression by recombinant human interferons: Enhanced targeting of monoclonal antibodies to carcinomas. Cancer Treat Res 1990;51:413.
5. Meredith R, Alvarez R, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177 Lu-CC49. Minerva Biotecnologica 1998;10:100.
6. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 2001;16:305.
7. Alvarez RD, Huh WK, Khazaeli MB, et al. A Phase I study of combined modality (90) Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806.
8. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci U S A 1989;86:4220.
9. Allison P. Survival Analysis Using SAS-: A Practical Guide. SAS Publishing, Cary, NC; 1995.
10. Allison P. Missing Data (Sage University Series on Quantitative Applications in the Social Sciences, series no. 07-136). Sage Publications, Thousand Oaks, CA, 2001.
11. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175.
12. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103.
13. Le T, Krepart GV, Lotocki RJ, Heywood MS. Malignant mixed mesodermal ovarian tumor treatment and prognosis: A 20-year experience. Gynecol Oncol 1997;65:237.
14. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248.
15. Elgqvist J, Andersson H, Back T, et al. Alpharadioimmunotherapy of intraperitoneally growing OVCAR- 3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342.
16. Epenetos AA, Munro AJ, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987;5:1890.
17. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, et al. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;2:894.
18. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003;21(Suppl10): 187s.
19. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413.
20. Meredith R, Ding S, Alvaraz R, et al. Predictors of long term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. Am J Clin Oncol 2010;32:205.